Note: This story was updated March 21, 2024, to correct that NeuroDerm is a subsidiary of Mitsubishi Tanabe Pharma Corp. ND0612, a liquid formation of levodopa/carbidopa given without interruption via an under-the-skin pump, continues to outperform standard oral levodopa/carbidopa at controlling motor symptoms in people with advanced…
News
When asked to quickly assess the number of people in a room, the average person tends to overcount them. In Parkinson’s disease patients with presence hallucinations — the strong sensation of a presence when no one is there — this overestimation is much more heightened when compared with patients…
Four months of daily Nuplazid (pimavanserin), an approved oral therapy for psychosis associated with Parkinson’s disease, was also found to significantly improve cognitive abilities, daily living activities, and health-related quality of life for patients in a Phase 4 study. “These findings suggest that treatment with [Nuplazid] can result…
Playing rehabilitative video games along with physical therapy is more effective than conventional physical therapy only for managing symptoms of Parkinson’s disease, a study suggests. Video game-based therapy is also a better add-on to traditional physical therapy than motor imagery where a patient visualizes the steps needed for complex…
BioVie is planning to launch in late summer a Phase 2b clinical trial of NE3107, its investigational anti-inflammatory small molecule, as an initial and stand-alone treatment for Parkinson’s disease, the company announced in a release. The trial aims to recruit between 100 and 150 newly diagnosed Parkinson’s…
Produodopa (foslevodopa/foscarbidopa; also known as ABBV-951), a continuous infusion formulation of levodopa/carbidopa, will be available to advanced Parkinson’s disease patients in Scotland whose severe motor fluctuations and involuntary movements are no longer controlled by those standard therapies. The Scottish Medicines Consortium (SMC) restricted use of AbbVie’s subcutaneous…
Ventyx Biosciences plans to launch a Phase 2a clinical trial testing VTX3232, an oral medication designed to reduce inflammation by blocking the activity of the NLRP3 protein, in people with early Parkinson’s disease in the second half of this year. Top-line results from a Phase 1 study in healthy…
An artificial intelligence (AI)-based software called NetraAI was able to separate subgroups of Parkinson’s disease patients based on their gene activity patterns, helping to better understand the complex pathways that contribute to the neurodegenerative disease. Through the analysis, scientists identified immune signaling as an important disease-related process. The function…
Monte Rosa Therapeutics is running preclinical studies testing MRT-8102, an orally available molecular glue degrader that targets NEK7, a protein needed to set off a type of inflammatory response involved in diseases including Parkinson’s. The studies are a key step in the process of seeking approval for clinical…
Allyx Therapeutics will advance into Phase 2 clinical development of ALX-001, its investigational therapy for neurodegenerative conditions, in people with Parkinson’s disease. The company announced the move alongside the presentation of positive data from a Phase 1b study (NCT05804383) at the International Conference on Alzheimer’s and…
Recent Posts
- New $2M MJFF grant backs Parkinson’s walking study at Boston University
- My fear of falling has gotten worse since my Parkinson’s diagnosis
- New compound targets mitochondrial damage in Parkinson’s models
- Environmental factors may impact Parkinson’s disease risk: Dutch study
- Finding solutions for REM sleep behavior disorder with Parkinson’s